Envista
DEXIS™IS ScanFlow v.1.0.10 adds new series of guided workflows and AI enhancements to optimize the dental implant workflow.
QUAKERTOWN, PA / ACCESSWIRE / March 19, 2024 / Earlier this year, DEXIS launched its dental implant ecosystem so clinicians can manage their entire implant workflow, from diagnosis to delivery, with one integrated toolset. To enhance workflow efficiencies, DEXIS announces the release of a new intraoral scanning update, DEXIS™IS ScanFlow v.1.0.10. The update includes a new series of guided workflows, enhancements to its AI capabilities, and an integration with DEXIS Imaging Suite software version 10.
"We are excited to introduce our latest DEXIS intraoral scanning software update, aimed at boosting productivity for DEXIS software owners and implant workflows," says Brian Gooch, VP of Marketing at DEXIS. "We've made scanning fast and easy, even for more complex situations. Digital impression data is important for implant case planning, so we enable highly accurate data to be incorporated into chairside or open workflows, and easily shared with labs or colleagues."
The IS ScanFlow software update maintains high-speed scanning, user-friendly interface, precise data capture, and an open, flexible system. Early adopters have provided positive feedback, highlighting the system's ease of use and its ability to reliably capture accurate data.
Early adopters have reported positive feedback, highlighting the wide range of cases they're able to accurately capture data for:
"The DEXIS IS 3800W intraoral scanner and its predecessors have enabled me to apply digital dentistry to all my prosthetic and implant cases," says Dr. Sebastian Patzelt. "Now, with the new AI applications in DEXIS IS ScanFlow, I'm able to digitize the soft and hard tissues of the oral cavity for fixed, removable or implant cases accurately and efficiently. *"
IS ScanFlow v1.0.10 aims to maximize productivity through AI-driven tools for dentists.
The new release adds a brand-new AI Matching tool that simplifies data capture in complex situations like multiple scan bodies, full and partial edentulism.
It also includes algorithm enhancements to its Implant Scan Body AI Assist tool which automatically detects scan bodies and reduces noise in the data, corrects artifacts and enhances details - furthering the automation of precise data capture.
IS ScanFlow v 1.0.10 introduces guided dental workflows to cut manual tasks and simplify processes.
Users now have the flexibility to fill out case information before initiating scanning or after completion, thanks to the new CaseFlow Manager tool. Regardless of the chosen option, users can then move into an easy, guided workflow that automates manual processes, predicts next steps, and assists in acquiring data for the selected indication.
The brand-new Full Arch Implant workflow guides users through the data-capture workflow for a full arch case and then automatically aligns the scans in occlusion, allowing for one consolidated dataset to send to a lab or manufacturer.
IS ScanFlow v 1.0.10 also facilitates efficient lab communication by enabling users to view case progress and real-time lab status updates directly within the Patient History screen. This allows easy collaboration, reduction in delays, and timely completion of tasks.
IS ScanFlow integrates with DTX Studio™ Clinic to connect the implant workflow
"The true power of IS ScanFlow is seen when paired with the core of the DEXIS implant ecosystem-DTX Studio Clinic," says Brian Gooch, VP of Marketing at DEXIS. "Packed with smart tools and advanced algorithms, DTX Studio Clinic serves as the clinic's imaging homebase, diagnostic hub, and treatment planning navigator. It connects each step of the implant process together and now, when purchased with an intraoral scanner, comes at no extra cost.
"Implant workflow productivity can be maximized by integrating IS ScanFlow into the rest of the tools and software within the DEXIS digital ecosystem - where practices can manage an entire implant case, from diagnosis to delivery, with one integrated toolset."
To learn more about DEXIS and the latest IS ScanFlow software version, visit https://www.dexis.com.
About DEXIS
DEXIS has been a global leading brand in digital radiography for 70+ years. Today, DEXIS has brought together the most trusted brands in 3D imaging, intraoral scanning solutions, and diagnostic software to provide patients with a complete digital diagnostic solution under a brand name. Our innovative award-winning technology enhances how the patient is diagnosed, accelerates the workflow, and delivers simple treatment paths with better patient outcomes. For more information, please visit https://www.dexis.com.
*Dr. Robert Pauley is a paid consultant for DEXIS
Contact Information
Hayley Reed
Regional Marketing Director, DEXIS IOS
hayley.reed@envistaco.com
(714) 628-8533
SOURCE: DEXIS
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release
Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e
Ascend Advanced Therapies - ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy8.1.2026 13:00:00 CET | Press release
Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice President of Global Business Development Appointments underscore Ascend-ABL's commitment to scientific rigor, operational excellence, and strategic growth ROCKVILLE, MARYLAND / ACCESS Newswire / January 8, 2026 / Ascend Advanced Therapies - ABL Inc. today announced significant appointments to its leadership team. Seiga Ohmine Ph.D. joins as Chief Commercial Officer (CCO) Sharad Dubey CA, CPA joins as Chief Financial Officer (CFO) Patrick Lansky joins as Senior Vice President of Global Business Development These appointments reflect Ascend-ABL's focus on strengthening scientific leadership, operational discipline, and customer-centric execution as the company sharpens its positioning as a trusted CDMO partner for advanced viral modalities. Commenting on the appointments, Alessandra Rispoli, Chief Executive Officer of Ascend-ABL said, "We are making strong progress
Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI8.1.2026 08:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / January 8, 2026 / Market Logic Software is excited to announce a technology partnership with Zappi designed to help leading brands develop, refine, and test new product concepts faster than ever before. United by a joint agentic AI framework, this collaboration brings together advanced AI capabilities from both companies, marking a pivotal shift in how organizations execute insights-driven innovation. Through AI-to-AI integrations, linking two powerful AI platforms, enterprises can now enrich their product innovation process with a comprehensive data ecosystem. Specially trained DeepSights AI agents within Market Logic's Innovation Studio continuously monitor, analyse, and synthesize market research, news, and operational data-allowing for accelerated concept generation and more informed decision-making. With just a couple of clicks, customers can seamlessly progress to testing their concepts with real people, thanks to Zappi's real-world respondent solut
RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.7.1.2026 22:20:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF) ("RE Royalties" or the "Company") is pleased to announce that it has entered into a definitive agreement with Solaris Energy Inc. ("Solaris") to invest up to USD $9.0 million to acquire a royalty interest (the "Royalty Purchase") in two portfolios of distributed generation ("DG") solar projects located throughout the United States. The first portfolio consists of 15 projects including 9 under construction with several nearing operation, and 6 in development, located across California, Maine, Delaware, New Hampshire and Colorado ("Portfolio 1"). The second portfolio comprises 9 more projects, the final composition of which may evolve as the projects advance ("Portfolio 2"). The transaction represents the acquisition of a portfolio level royalty on a diversified portfolio of DG solar assets and marks the exciting beginning of a new partnership between the two parties. The Royalty Purchase for Por
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
